PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Clinical Pharmacy Department, Pharmacy Services Administration, King Fahad Medical City, Riyadh, Saudi Arabia.\', \'Infectious Diseases Section, Department of Medical Specialties, King Fahad Medical City, Riyadh, Saudi Arabia.\', \'Sharjah Medical Institute of Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.\', \'Clinical Research Coordinator, Collage of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia.\', \'Outpatient Pharmacy Department, Pharmacy Services Administration, King Fahad Medical City, Riyadh, Saudi Arabia.\', \'Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.\', \'Prince Abdullah Ben Khaled Celiac Disease Chair, Department of Pediatrics, Faculty of Medicine, King Saud University, Saudi Arabia.\', \'College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.\', \'Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States of America.\', \'Division of Epidemiology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States of America.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1371/journal.pone.0252984
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 34111191
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
is ?:relation_isRelatedTo_publication of
?:title
  • Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all